Syngeneic Mouse Models

Extensively validated syngeneic mouse models for preclinical immunotherapy research.

Syngeneic mouse models excel where xenograft mouse models come short. The goal of cancer immunotherapies is to promote the patient’s native anti-tumor response. Xenograft mouse models are therefore flawed in cancer immunotherapy research, given that they are devoid of a proper immune system. This is where syngeneic mouse models fill the gap: they show us how cancer immunotherapies perform with a functioning immune system.

At PharmaLegacy, we can provide you with a panel of syngeneic mouse models (22 models in total covering 14 cancer types), validated with anti-PD-1, PD-L1 and anti-CTLA-4 antibodies. Our team is hard at work to provide you with even better, newer models.

Keep checking our website for updates on the models that are still under-development, or contact us for any model development needs.

Syngeneic Mouse Models

Models / Services

PharmaLegacy provides a panel of extensively-validated syngeneic mouse models for preclinical immunotherapy research, used to interrogate novel immune-oncology treatments. We have model types including subcutaneous, orthotopic and metastatic. Our suite of syngeneic mouse models includes 22 models covering 14 cancer types, which have been validated with anti-PD-1, PD-L1 and anti-CTLA-4 antibodies. Additional models are in development.

Mouse PD1 and CTLA4 Ab Test in CT26 Model

Animal: Female BALB/c mice (from SLAC), 7~8 weeks.

Tumor Cell: CT26.WT, subcutaneous implantation.

Reagent: Anti-m-CTLA-4, Anti-m-PD-1

Dosing started on Day10 post inoculation.

Animal: Female BALB/c mice (from SLAC), 4~5 weeks.

Tumor Cell: CT26.WT, subcutaneous implantation.

Reagent: Anti-m-PD-1 5mg/kg QW*3 i.p.

Anti-m-PD-1 1mg/kg QW*3 i.p.

Animal:  Female C57BL/6 mice (from SLAC), 5~6 weeks.

Tumor Cell:  H22, subcutaneous implantation.

Reagent:Anti-m-PD-1 5mg/kg QW*3 i.p.

PD-L1PD1/ Ab Dose-Finding for Combination(mc-38)

Animal:  Female C57BL/6 mice (from SLAC), 5~6 weeks.

Tumor Cell:  MC-38, subcutaneous implantation.

Reagent1:  Anti-m-PD-1 5mg/kg QW*3 i.p.

Anti-m-PD-1 1mg/kg QW*3 i.p.

Reagent2:  Anti-m-PD-L1 5mg/kg BIW*3 i.p.

Anti-m-PD-L1 5mg/kg QW*3 i.p.

Immunocyte-Profiling in Tumor in MC-38 Model

G4: PD-L1 Ab

The capability to succeed:

  • Rigorous adherence to international GLP and QA best practices
  • Operations and IT structured for maximum protection of clients’ data and IP
  • Completed over 400 FDA / CFDA IND filings
  • 43,000 square feet of vivarium space

Looking for a CRO that can deliver pipeline breakthroughs? Contact PharmaLegacy.

Contact Us

Top Pharmaceutical Companies Trust PharmaLegacy for their Oncology Trials

“The study they delivered on a very reasonable budget was top notch […] The model was executed flawlessly.”

See why a top-20 pharmaceutical company trusts PharmaLegacy for their preclinical immuno-oncology trials.





    Immuno-Oncology-Case-Study-Brochure Image

    We’re ready when you are.

    Tell us your pharmacology challenges.